Loviride

Drugbox
IUPAC_name = 2- [(2-Acetyl-5-methylphenyl)amino] -2-(2,6-dichlorophenyl)acetamide


CAS_number =
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 3963
DrugBank =
C=17 | H=16 | Cl=2 | N=2 | O=2
molecular_weight = 351.227 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Loviride (also called Loveride) was an antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is an NNRTI that entered phase III clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials Loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to all NNRTI's.

ynonyms

*Loveride
*R089439

External links

* [http://www.aidsmap.com/cms1032278.asp aidsmap]